Siva is pleased to announce 
that it has entered into a merger 
agreement with
Sona Nanotech Inc.

Screen Shot 2021-07-27 at 7.16.51 PM

Siva Therapeutics’ goal is to develop the next generation of interventional oncology that is less invasive, safer, more effective, less costly, and more practical than current cancer therapies on the market. Currently, cancer patients face treatments that are invasive, risky, disfiguring, moderately effective at best, and very costly.


Siva is developing Targeted HyperthermiaTM (THT), an elegant, safe and effective cancer therapy which generates therapeutic heat within solid tumors using SivaRodsTM gold nanorods and a SivaLumTM infrared light device. THT has multiple beneficial effects on tumors, and it is more selective than chemotherapy, less destructive than radiation, and without the risks of surgical treatment.  This treatment promises to be minimally invasive, to reduce harmful side effects, and to stimulate the immune system.  In addition to being more affordable, this technology promises to deliver faster results than current cancer treatments.   

Siva’s approach is to use SivaRodsTM gold nanorods and SivaLumTM infrared light device to destroy solid tumors with THT and improve patient health and outcome. To learn about our approach and technology, visit our technology page.  

Hyperthermia improves patient outcomes for every cancer indication for which it has been investigated.